A Phase I Trial of Tecogalan Sodium ( DS-4152 ) Administered as an Infusion Weekly x 4
NCT00002137 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL
Last updated 2005-06-24
Summary
To evaluate the safety of different doses and dosing regimens of tecogalan sodium (DS-4152) and to establish the MTD at each of the different dosing schedules.
Conditions
- Sarcoma, Kaposi
- HIV Infections
Interventions
- DRUG
-
Tecogalan sodium
Sponsors & Collaborators
-
Daiichi Pharmaceuticals
lead INDUSTRY
Study Design
- Purpose
- TREATMENT
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
Countries
- United States
Study Locations
More Related Trials
-
Open-Label Study to Assess the Safety/Tolerability in Patients With Solid Tumors
NCT00820560 ·Status: COMPLETED ·Phase: PHASE1
-
Tandem High Dose Chemotherapy With 131I-MIBG Treatment in High Risk Neuroblastoma
NCT03061656 ·Status: UNKNOWN ·Phase: PHASE2
-
Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery
NCT00608361 ·Status: COMPLETED ·Phase: PHASE1
-
First-in-Human Trial of DS-2243a in Participants With Advanced Solid Tumors
NCT06644755 ·Status: RECRUITING ·Phase: PHASE1
-
A Study of Atezolizumab (Tecentriq®) in Ministry of Food and Drug Safety (MFDS)-Approved Indication(s)
NCT03232593 ·Status: COMPLETED
-
Lenalidomide, Docetaxel, and Carboplatin in Treating Patients With Advanced Solid Tumors
NCT00415116 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of KC1036 in Adolescents With Advanced Ewing Sarcoma
NCT06564272 ·Status: RECRUITING ·Phase: PHASE2
-
Study of DS-1123a in Advanced Solid Tumours
NCT02690337 ·Status: COMPLETED ·Phase: PHASE1
-
CHS 828 in Treating Patients With Solid Tumors
NCT00003979 ·Status: WITHDRAWN ·Phase: PHASE1
-
Carbendazim in Treating Patients With Advanced Solid Tumors or Lymphoma
NCT00023816 ·Status: UNKNOWN ·Phase: PHASE1
-
Study Evaluating TTI-237 in Advanced Malignant Solid Tumors
NCT00195247 ·Status: TERMINATED ·Phase: PHASE1
-
KRN5500 in Treating Patients With Solid Tumors
NCT00017238 ·Status: COMPLETED ·Phase: PHASE1
-
MEN-10755 in Treating Patients With Solid Tumors
NCT00003982 ·Status: COMPLETED ·Phase: PHASE1
-
Phase 1 Dose Escalation and Dose Expansion Trial of NP-101 in Patients With Solid Tumors
NCT06563375 ·Status: RECRUITING ·Phase: PHASE1
-
Chemotherapy in Treating Patients With Advanced or Metastatic Solid Tumors
NCT00003713 ·Status: COMPLETED ·Phase: PHASE1
-
Study of DS-8201a in Subjects With Advanced Solid Malignant Tumors
NCT02564900 ·Status: COMPLETED ·Phase: PHASE1
-
PEG-rhG-CSF in Patients With Malignant Solid Tumors Receiving Chemotherapy
NCT02805166 ·Status: COMPLETED ·Phase: PHASE4
-
Safety/Tolerability Study of AV-412 in Subjects With Refractory or Relapsed Solid Tumor Malignancies
NCT00381654 ·Status: TERMINATED ·Phase: PHASE1
-
Phase 1 Study of DS-6051b in Japanese Subjects With Advanced Solid Malignant Tumors
NCT02675491 ·Status: COMPLETED ·Phase: PHASE1
-
A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of E6201 in Subjects With Advanced Solid Tumors
NCT00794781 ·Status: COMPLETED ·Phase: PHASE1
-
Genetic Testing Plus Irinotecan in Treating Patients With Solid Tumors or Lymphoma
NCT00003970 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of TAK-441 in Adult Patients With Advanced Nonhematologic Malignancies
NCT01204073 ·Status: COMPLETED ·Phase: PHASE1
-
Safety Assessment of Weekly Intravenous Infusions of SNS-595 for the Treatment of Solid Tumors
NCT00094159 ·Status: COMPLETED ·Phase: PHASE1
-
AZD1152 in Patients With Advanced Solid Malignancies-Study 1
NCT00497731 ·Status: TERMINATED ·Phase: PHASE1
-
Study of Dasatinib in Patients With Advanced Solid Tumors
NCT00162214 ·Status: TERMINATED ·Phase: PHASE1